Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus V CILLIN.
BACTOCILL vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic